Advertisement

Effect of Statins on Recurrent Venous Thromboembolism (from the COMMAND VTE Registry)

Published:October 29, 2019DOI:https://doi.org/10.1016/j.amjcard.2019.10.011
      Statins, which are considered as essential for primary and secondary prevention of atherosclerotic diseases, were also reported to reduce first venous thromboembolism (VTE). However, the effect of statins on VTE recurrence remains conflicting. We aimed to examine the association between statin use and VTE recurrence in a large observational study in Japan. The COMMAND VTE Registry is a multicenter registry enrolling consecutive 3027 patients with acute symptomatic VTE in 29 centers in Japan between January 2010 and August 2014. In the current study, the entire cohort was divided into statin group (N = 437) and no-statin group (N = 2590) according to the status of statin use at baseline. The statin group as compared with the no-statin group was older (statin group 71.2 vs no-statin group 66.5 years, p <0.001), included more women (67% vs 60%, p = 0.008), and less frequently had active cancer (12% vs 25%, p <0.001). There was no significant difference in the clinical presentation of VTE (pulmonary embolism, 58% vs 56%, p = 0.44). The cumulative 3-year incidence of recurrent VTE was significantly lower in the statin group than the no-statin group (3.8% vs 8.8%, p <0.001). After adjusting for confounders including active cancer, statin use was associated with significantly lower risk for recurrent VTE (Hazard ratio 0.49, 95% confidence interval 0.29 to 0.78, p = 0.002). The results were consistent in a sensitivity sub-group analysis with and without active cancer. In conclusion, statin use was associated with significantly lower risk for the recurrent VTE in patients with VTE.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Oesterle A
        • Laufs U
        • Liao JK
        Pleiotropic effects of statins on the cardiovascular system.
        Circ Res. 2017; 120: 229-243
        • Undas A
        • Celińska-Löwenhoff M
        • Kaczor M
        • Musial J
        New nonlipid effects of statins and their clinical relevance in cardiovascular disease.
        Thromb Haemost. 2004; 91: 1065-1077
        • Violi F
        • Calvieri C
        • Ferro D
        • Pignatelli P
        Statins as antithrombotic drugs.
        Circulation. 2013; 127: 251-257
        • Glynn RJ
        • Danielson E
        • Fonseca FAH
        • Genest J
        • Gotto AM
        • Kastelein JJP
        • Koenig W
        • Libby P
        • Lorenzatti AJ
        • MacFadyen JG
        • Nordestgaard BG
        • Shepherd J
        • Willerson JT
        • Ridker PM
        A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
        N Engl J Med. 2009; 360: 1851-1861
        • Biere-Rafi S
        • Hutten BA
        • Squizzato A
        • Ageno W
        • Souverein PC
        • de Boer A
        • Gerdes VEA
        • Büller HR
        • Kamphuisen PW
        Statin treatment and the risk of recurrent pulmonary embolism.
        Eur Heart J. 2013; 34: 1800-1806
        • Tagalakis V
        • Eberg M
        • Kahn S
        • Azoulay L
        Use of statins and reduced risk of recurrence of VTE in an older population. A population-based cohort study.
        Thromb Haemost. 2016; 115: 1220-1228
        • Delluc A
        • Tromeur C
        • Le Moigne E
        • Nowak E
        • Mottier D
        • Le Gal G
        • Lacut K
        Lipid lowering drugs and the risk of recurrent venous thromboembolism.
        Thromb Res. 2012; 130: 859-863
        • Braekkan SK
        • Caram-Deelder C
        • Siegerink B
        • van Hylckama Vlieg A
        • le Cessie S
        • Rosendaal FR
        • Cannegieter SC
        • Lijfering WM
        Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study.
        Res Pract Thromb Haemost. 2017; 1: 112-119
        • Yamashita Y
        • Morimoto T
        • Amano H
        • Takase T
        • Hiramori S
        • Kim K
        • Konishi T
        • Akao M
        • Kobayashi Y
        • Inoue T
        • Oi M
        • Izumi T
        • Takahashi K
        • Tada T
        • Chen P-M
        • Murata K
        • Tsuyuki Y
        • Sakai H
        • Saga S
        • Sasa T
        • Sakamoto J
        • Yamada C
        • Kinoshita M
        • Togi K
        • Ikeda T
        • Ishii K
        • Kaneda K
        • Mabuchi H
        • Otani H
        • Takabayashi K
        • Takahashi M
        • Shiomi H
        • Makiyama T
        • Ono K
        • Kimura T
        • COMMAND VTE Registry Investigators
        Anticoagulation therapy for venous thromboembolism in the real world - from the COMMAND VTE Registry.
        Circ J. 2018; 82: 1262-1270
        • Yamashita Y
        • Morimoto T
        • Amano H
        • Takase T
        • Hiramori S
        • Kim K
        • Oi M
        • Akao M
        • Kobayashi Y
        • Toyofuku M
        • Izumi T
        • Tada T
        • Chen P-M
        • Murata K
        • Tsuyuki Y
        • Saga S
        • Sasa T
        • Sakamoto J
        • Kinoshita M
        • Togi K
        • Mabuchi H
        • Takabayashi K
        • Watanabe H
        • Shiomi H
        • Kato T
        • Makiyama T
        • Ono K
        • Kimura T
        • COMMAND VTE Registry Investigators
        Influence of baseline platelet count on outcomes in patients with venous thromboembolism (from the COMMAND VTE Registry).
        Am J Cardiol. 2018; 122: 2131-2141
        • Goldhaber SZ
        • Visani L
        • De Rosa M
        Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).
        Lancet. 1999; 353: 1386-1389
        • Meissner MH
        • Moneta G
        • Burnand K
        • Gloviczki P
        • Lohr JM
        • Lurie F
        • Mattos MA
        • McLafferty RB
        • Mozes G
        • Rutherford RB
        • Padberg F
        • Sumner DS
        The hemodynamics and diagnosis of venous disease.
        J Vasc Surg. 2007; 46: 4S-24S
        • Pollack CV
        • Schreiber D
        • Goldhaber SZ
        • Slattery D
        • Fanikos J
        • O'Neil BJ
        • Thompson JR
        • Hiestand B
        • Briese BA
        • Pendleton RC
        • Miller CD
        • Kline JA
        Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry).
        J Am Coll Cardiol. 2011; 57: 700-706
        • Laporte S
        • Mismetti P
        • Décousus H
        • Uresandi F
        • Otero R
        • Lobo JL
        • Monreal M
        • RIETE Investigators
        Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.
        Circulation. 2008; 117: 1711-1716
        • Büller HR
        • Décousus H
        • Grosso MA
        • Mercuri M
        • Middeldorp S
        • Prins MH
        • Raskob GE
        • Schellong SM
        • Schwocho L
        • Segers A
        • Shi M
        • Verhamme P
        • Wells P
        Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
        N Engl J Med. 2013; 369: 1406-1415
        • Schulman S
        • Kearon C
        • Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
        Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Faller N
        • Limacher A
        • Méan M
        • Righini M
        • Aschwanden M
        • Beer JH
        • Frauchiger B
        • Osterwalder J
        • Kucher N
        • Lämmle B
        • Cornuz J
        • Angelillo-Scherrer A
        • Matter CM
        • Husmann M
        • Banyai M
        • Staub D
        • Mazzolai L
        • Hugli O
        • Rodondi N
        • Aujesky D
        Predictors and causes of long-term mortality in elderly patients with acute venous thromboembolism: a prospective cohort study.
        Am J Med. 2017; 130: 198-206
        • Konstantinides SV
        • Torbicki A
        • Agnelli G
        • Danchin N
        • Fitzmaurice D
        • Galiè N
        • Gibbs JSR
        • Huisman MV
        • Humbert M
        • Kucher N
        • Lang I
        • Lankeit M
        • Lekakis J
        • Maack C
        • Mayer E
        • Meneveau N
        • Perrier A
        • Pruszczyk P
        • Rasmussen LH
        • Schindler TH
        • Svitil P
        • Vonk Noordegraaf A
        • Zamorano JL
        • Zompatori M
        Task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
        Eur Heart J. 2014; 35: 3033-3080
        • Jaff MR
        • McMurtry MS
        • Archer SL
        • Cushman M
        • Goldenberg N
        • Goldhaber SZ
        • Jenkins JS
        • Kline JA
        • Michaels AD
        • Thistlethwaite P
        • Vedantham S
        • White RJ
        • Zierler BK
        • American Heart Association Council on Cardiopulmonary
        • Critical Care, Perioperative and Resuscitation
        • American Heart Association Council on Peripheral Vascular Disease
        • American Heart Association Council on Arteriosclerosis
        • Thrombosis and Vascular Biology
        Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.
        Circulation. 2011; 123: 1788-1830
        • Kearon C
        • Akl EA
        • Ornelas J
        • Blaivas A
        • Jimenez D
        • Bounameaux H
        • Huisman M
        • King CS
        • Morris TA
        • Sood N
        • Stevens SM
        • Vintch JRE
        • Wells P
        • Woller SC
        • Moores L
        Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.
        Chest. 2016; 149: 315-352
        • JCS Joint Working Group
        Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009).
        Circ J. 2011; 75: 1258-1281
        • Ageno W
        • Becattini C
        • Brighton T
        • Selby R
        • Kamphuisen PW
        Cardiovascular risk factors and venous thromboembolism: a meta-analysis.
        Circulation. 2008; 117: 93-102
        • Arshad N
        • Bjøri E
        • Hindberg K
        • Isaksen T
        • Hansen JB
        • Braekkan SK
        Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
        J Thromb Haemost. 2017; 15: 295-303
        • Kunutsor SK
        • Seidu S
        • Khunti K
        Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies.
        Eur Heart J. 2017; 38: 1608-1612
        • Hemkens LG
        • Benchimol EI
        • Langan SM
        • Briel M
        • Kasenda B
        • Januel J-M
        • Herrett E
        • Elm von E
        The reporting of studies using routinely collected health data was often insufficient.
        J Clin Epidemiol. 2016; 79: 104-111
        • Notarbartolo A
        • Davì G
        • Averna M
        • Barbagallo CM
        • Ganci A
        • Giammarresi C
        • La Placa FP
        • Patrono C
        Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia.
        Arterioscler Thromb Vasc Biol. 1995; 15: 247-251
        • Chaffey P
        • Thompson M
        • Pai AD
        • Tafreshi AR
        • Tafreshi J
        • Pai RG
        Usefulness of statins for prevention of venous thromboembolism.
        Am J Cardiol. 2018; 121: 1436-1440
        • Colli S
        • Eligini S
        • Lalli M
        • Camera M
        • Paoletti R
        • Tremoli E
        Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.
        Arterioscler Thromb Vasc Biol. 1997; 17: 265-272